NCT02637531 2022-04-04A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Infinity Pharmaceuticals, Inc.Phase 1 Unknown219 enrolled
NCT00423254 2010-08-03Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.Mannkind CorporationPhase 1 Completed12 enrolled